TIGIT Inhibitors – Market Opportunity, Pipeline & Competitive Intelligence 2020
This TIGIT report covers the TIGIT market opportunity providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc)
By: mellalta meets
TIGIT has emerged as a key inhibitor of anti-tumor responses that can hinder multiple stages of the cancer immune cycle. The precise mechanism of action remains unclear and may have both cell-intrinsic and cell-extrinsic components; it can, for example, prevent NK from releasing tumor antigens cells, alter the priming of T cells by DCs or inhibit the killing of cancer cells by CD8+ T cells. The expression of TIGIT frequently occurs in parallel with the expression of other co-inhibitory receptors, in particular PD-1, where it acts synergistically to regulate the antitumor response.
The diverse function of TIGIT in multiple cell types has made it a profitable candidate for immunotherapy, with an increasing number of candidates being studied in preclinical and clinical settings. Preclinical studies have indicated that TIGIT blockade can protect against various solid and hematological cancers. Several monoclonal antibodies (mAbs) have been developed that block the inhibitory activity of human TIGIT. Studies combining antibodies against TIGIT with ICI of the PD-1 / PD-L1 pathway have become particularly interesting in light of the data showing the co-expression of TIGIT and PD-L1 in many types of cancer. Clinical trials are underway studying TIGIT blockade alone or in combination with PD1 / PD-L1 antibodies for the treatment of patients with advanced solid tumors.
The mechanism has piqued the interest from Merck and Roche, with the latter having the most advanced candidate, tiragolumab. There are more than 15 companies exploring their candidates. This report covers the TIGIT Market Opportunities (https://mellalta.com/
Key Takeaways from the Report
• Indication Prioritisation:
• Business Transactions & Strategies: Key collaborations and deal values
• TIGIT Pipeline Development:
• TIGIT Acquisition Targets
• TIGIT Competitive Intelligence
• Recent & Upcoming events
Contact us: email@example.com